Claruvis Pharmaceutical Launches Groundbreaking Recombinant Botulinum Toxin Drug in China
In a groundbreaking development for the pharmaceutical industry, Chongqing Claruvis Pharmaceutical Co., Ltd. has announced that the National Medical Products Administration of China (NMPA) has approved its innovative product, Retoxin® — the world’s first approved recombinant botulinum toxin type A. This monumental event is set to shift the landscape of aesthetic and therapeutic applications of neurotoxins significantly.
Retoxin® represents a substantial advancement from traditional botulinum toxin products that were derived from natural sources, namely the bacterium Clostridium botulinum. This new compound was created using state-of-the-art recombinant technology aimed at precisely engineering the neurotoxin’s properties. By employing their exclusive recombinant manufacturing platform, Claruvis has successfully retained the active molecular structure of the neurotoxin while excluding the conventional risks associated with the wild-type organism. The result is a product that boasts high purity and specific activity — crucial factors for both efficacy and safety in clinical applications.
In a multicenter, randomized, double-blind, placebo-controlled trial involving adult participants, Retoxin® has demonstrated remarkable results. The study met all primary and secondary endpoints for efficacy, exhibiting an impressive safety profile and low immunogenicity. These findings indicate the potential of recombinant technology to yield superior products for both aesthetic enhancements and clinical therapies, setting a new standard in the industry.
Beyond its initial approval for treating moderate to severe glabellar lines (frown lines), Claruvis Pharmaceutical is also developing Retoxin® for additional therapeutic uses. Specifically, the company is focusing on treating upper limb spasticity post-stroke or traumatic brain injuries. Following successful completion of phase II clinical trials, the company is actively enlisting patients for an extensive phase III study across over 20 clinical sites in China. Through this endeavor, Claruvis aims to provide a safer and more effective treatment option for individuals suffering from debilitating spasticity.
Dr. Yang, the Chief Scientific Officer at Claruvis Pharmaceutical, expressed, "Retoxin® marks the commercial launch of our recombinant platform and affirms our vision of developing next-generation botulinum toxins that prioritize purity, consistency, and improved safety." The company is committed to building a robust portfolio of recombinant products to address a wide range of neurological and aesthetic indications, positioning itself as a leader in biopharmaceutical innovation.
Mr. Liu, the company’s CEO, remarked on the significance of the Chinese approval, stating, "This is a pivotal moment for our company. We are determined to advance our innovative recombinant botulinum toxin portfolio and offer groundbreaking therapeutic options to patients and clinicians worldwide."
Chongqing Claruvis Pharmaceutical Co., Ltd., a subsidiary of MingMed Biotechnology, is a biopharmaceutical firm dedicated to innovation. With a focus on research, development, manufacturing, and commercialization of recombinant botulinum toxin products, Claruvis has braved the shift from traditional extraction methods to precision recombinant production, ensuring the delivery of safer and higher-quality medications for both aesthetic and therapeutic uses globally. This exciting new chapter in neurotoxin therapy is just the beginning of what Claruvis aims to achieve in the pursuit of excellence in the pharmaceutical landscape.
A New Era of Botulinum Toxin
Retoxin® represents a substantial advancement from traditional botulinum toxin products that were derived from natural sources, namely the bacterium Clostridium botulinum. This new compound was created using state-of-the-art recombinant technology aimed at precisely engineering the neurotoxin’s properties. By employing their exclusive recombinant manufacturing platform, Claruvis has successfully retained the active molecular structure of the neurotoxin while excluding the conventional risks associated with the wild-type organism. The result is a product that boasts high purity and specific activity — crucial factors for both efficacy and safety in clinical applications.
Clinical Trials and Efficacy
In a multicenter, randomized, double-blind, placebo-controlled trial involving adult participants, Retoxin® has demonstrated remarkable results. The study met all primary and secondary endpoints for efficacy, exhibiting an impressive safety profile and low immunogenicity. These findings indicate the potential of recombinant technology to yield superior products for both aesthetic enhancements and clinical therapies, setting a new standard in the industry.
Future Applications and Developments
Beyond its initial approval for treating moderate to severe glabellar lines (frown lines), Claruvis Pharmaceutical is also developing Retoxin® for additional therapeutic uses. Specifically, the company is focusing on treating upper limb spasticity post-stroke or traumatic brain injuries. Following successful completion of phase II clinical trials, the company is actively enlisting patients for an extensive phase III study across over 20 clinical sites in China. Through this endeavor, Claruvis aims to provide a safer and more effective treatment option for individuals suffering from debilitating spasticity.
Celebrating Innovations in Biotechnology
Dr. Yang, the Chief Scientific Officer at Claruvis Pharmaceutical, expressed, "Retoxin® marks the commercial launch of our recombinant platform and affirms our vision of developing next-generation botulinum toxins that prioritize purity, consistency, and improved safety." The company is committed to building a robust portfolio of recombinant products to address a wide range of neurological and aesthetic indications, positioning itself as a leader in biopharmaceutical innovation.
Mr. Liu, the company’s CEO, remarked on the significance of the Chinese approval, stating, "This is a pivotal moment for our company. We are determined to advance our innovative recombinant botulinum toxin portfolio and offer groundbreaking therapeutic options to patients and clinicians worldwide."
About Claruvis Pharmaceutical
Chongqing Claruvis Pharmaceutical Co., Ltd., a subsidiary of MingMed Biotechnology, is a biopharmaceutical firm dedicated to innovation. With a focus on research, development, manufacturing, and commercialization of recombinant botulinum toxin products, Claruvis has braved the shift from traditional extraction methods to precision recombinant production, ensuring the delivery of safer and higher-quality medications for both aesthetic and therapeutic uses globally. This exciting new chapter in neurotoxin therapy is just the beginning of what Claruvis aims to achieve in the pursuit of excellence in the pharmaceutical landscape.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.